Screener
Praxis Precision Medicines, Inc. PRAX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001689548-26-000083
FAQ
- What is Praxis Precision Medicines, Inc.'s cash & equivalents?
- Praxis Precision Medicines, Inc. (PRAX) reported cash & equivalents of $474.76M in Q2 2026.
- How has Praxis Precision Medicines, Inc.'s cash & equivalents changed year-over-year?
- Praxis Precision Medicines, Inc.'s cash & equivalents increased by 200.8% year-over-year, from $157.83M to $474.76M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s cash & equivalents has grown at a 3.8% compound annual growth rate (CAGR), from $297.21M to $357.75M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Praxis Precision Medicines, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude